Press

Fabric Genomics announced that its proprietary clinical genomics platform has been selected by 10 new commercial partners across four continents, including Africa, Asia, Europe and North America. The company’s software is allowing these organizations to provide genomics leadership and state-of-the art clinical genomics testing in their respective countries. The new customers consist of hospitals, clinical …

An in-house laboratory at Intermountain Healthcare is starting to offer genetic testing to patients who have a history of cancer in their family to identify those who have …

This week, at the Association for Molecular Pathology (AMP) Annual Meeting, Fabric Genomics will announce its expanded somatic cancer solution which provides seamless genomic analysis and clinical reporting to clinical labs. The offering enables therapy matching for cancer patients, giving clinicians targeted treatment choices for cancer patients. Now clinical labs have one integrated platform for the interpretation …

Fabric Genomics has partnered with Genomics England’s 100,000 Genomes Project, Rady Children’s Institute for Genomic Medicine (RCIGM), and The Utah Genome Project (UGP), to provide fast and accurate identification of pediatric disease-causing variants to improve the clinical care of children. Fabric Genomics’ Opal™ Clinical is the only genomic interpretation and reporting platform to include the algorithms VAAST and Phevor, two pioneering …

Today at the American Society for Human Genetics (ASHG) Annual Meeting, Edico Genome and Fabric Genomics announced their collaboration to provide an integrated solution for secondary and tertiary analysis of next-generation sequencing data. Through this partnership, users can seamlessly utilize Edico Genome’s DRAGENTM Bio-IT platform with Fabric Genomics’ Opal™ Clinical variant interpretation platform to accurately gain biological insights into …

Fabric Genomics and Genome Medical announced today that they have entered into a partnership with the goal of bringing expert medical interpretation and counseling around genomic data directly to physicians and patients. Genome Medical will use Fabric Genomics’ clinical interpretation platform, Fabric Enterprise™, for ongoing examination of its patients’ genomic data to augment data analysis and annotation in collaboration …

Fabric Genomics, a global computational genomics company offering data analysis and clinical reporting tools, announced today that it has partnered with data management company ITTM S.A. (Information Technology for Translational Medicine) to provide secure genomic data hosting capabilities for EU customers. By combining Fabric Genomics’ leading analysis tools with ITTM’s proven secure hosting and infrastructure …

Fabric Genomics, a global computational genomics company, and TOMA Biosciences, a genomic cancer diagnostics company, announced today a partnership that will bring together premier chemistry and informatics platforms for deepened genomic analysis of cancer and delivery of clinically meaningful information for tumor profiling. The companies will co-develop an end-to-end oncology genomic testing and clinical interpretation …

Fabric Genomics, a global computational genomics company, and Veritas Genetics, the global leader in genetic sequencing and interpretation, announced today at the ACMG Annual Clinical Genetics Meeting that they have entered into a technology partnership. The goal of the collaboration is to accelerate Veritas’ myGenome product for personal whole genome sequencing using Fabric Genomics’ new …

Fabric Genomics, a global computational genomics company, and Sentieon, which develops highly optimized algorithms for bioinformatics applications, today announced a technology partnership that will enhance Fabric Genomics’ secondary analysis capabilities within Fabric Enterprise™, the company’s new end-to-end precision medicine platform. Fabric Genomics’ new secondary analysis offering, Fabric Standard™, is 10 times faster than commonly adopted …

Omicia, Inc., a leading provider of clinical genomic data analysis and reporting tools, was selected to join the Cancer Moonshot’s Blood Profiling Atlas in Cancer (Blood PAC) consortium. In joining Blood PAC, Omicia is demonstrating its commitment to advancing cancer genetics research and extending patients’ lives. The Blood PAC was formed in October 2016 in …

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that San Diego-based Rady Children’s Institute for Genomic Medicine has chosen the company as their first line genome interpretation partner for the implementation of Rady Children’s rapid genome testing in their neonatal and pediatric intensive care units (NICU/ PICU). Stephen Kingsmore, …

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that it has delivered more than 500 clinical reports for the 100,000 Genomes Project, and has begun to return clinical reports for the project’s main program. These clinical reports are being delivered to Genomics England, leader of the 100,000 Genomes Project, and …

Genomics England announced today that it has contracted with Omicia to interpret genomic data from the first 8,000 patients participating in the UK’s 100,000 Genomes Project.  

In the recent article “The DNA of a Nation,” Nature magazine highlights the highly-specialized and dedicated clinical interpretation services that Genomics England requires for their 100,000 Genomes Project, which is the first step in bringing genomics to the UK healthcare system. Omicia, the worldwide leader in genome informatics and clinical interpretation, was selected from 28 …

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, today announced the completion of a $23 million Series B financing round. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia …

Omicia announces the launch of its new ACMG-scoring module for the Opal Clinical™ interpretation and reporting software platform at the 2016 ACMG Annual Clinical Genetics Meeting. This functionality provides an intuitive interface and workflow for clinical testing labs to systematically assess the disease-causing potential of genetic variants using the evidence-based classification system defined in the …